Prostatic intraepithelial neoplasia and other changes during promotion and progression.
Preneoplastic lesions, early neoplastic lesions and carcinomas in situ have been demonstrated to be of great value for many purposes in many organ systems. Their recognition can be useful in epidemiological studies and can facilitate the selection of patients for therapeutic interventions. They can be used as "surrogate endpoint biomarkers" in studies aimed at the chemoprevention of cancers. In the lung, colon and various other organs, such markers are well recognized to be associated with the development of cancer in man. In the livers and colons of experimental animals, there has been detailed characterization of "enzyme-altered foci" (EAF) as "putative preneoplastic markers." The words "surrogate" and "putative" are important; the biological potential of these lesions needs to be elucidated in much greater detail. The quantification of early lesions that are associated with and sometimes precursors of neoplasia is of particular value because they are much more numerous, in most organ systems, than the carcinomas that develop in the same organs. The most abundant of these lesions show minimal or no morphological alterations. For example, EAF and aberrant crypts are more numerous than polyps in the colons of patients and experimental animals with cancer or precancerous conditions that affect the colon. Currently, there are few well documented putative or surrogate markers that are highly associated with the development of prostatic carcinoma in man. The best documented among these is prostatic intraepithelial neoplasia. We have recently reported the identification of EAF in the human prostate. While they share many phenotypic alterations with prostatic intraepithelial neoplasia, much remains to be accomplished if their biological fate is to be understood.
Pretlow
T G
TG
Institute of Pathology, Case Western Reserve University Medical Center, Cleveland, Ohio, USA.
Nagabhushan
M
M
Pretlow
T P
TP
D000818:Animals; D014408:Biomarkers, Tumor; D006801:Humans; D008297:Male; D011230:Precancerous Conditions / Q000201:enzymology / Q000276:immunology / Q000473:pathology*; D019048:Prostatic Intraepithelial Neoplasia / Q000201:enzymology / Q000276:immunology / Q000473:pathology*; D011471:Prostatic Neoplasms / Q000201:enzymology / Q000276:immunology / Q000473:pathology*; D051381:Rats
D014408:Biomarkers, Tumor